Inclusion Criteria

Inclusion criteria: Patients aged 18 or older with histological diagnosis of anaplastic
astrocytoma (WHO grade III) or glioma (WHO grade IV) Assigned to bevacizumab treatment
(monotherapy or adjunctive to chemotherapy) for therapeutic reasons by an oncologist
Patients should be on a stable or decreasing dose of steroids Willingness and ability to
comply with the protocol Patient should present with a KPS of >=70 Signed informed consent

Exclusion criteria: Previous anti-angiogenic drugs other than bevacizumab Allergy or
hypersensitivity against bevacizumab Contraindications to bevacizumab according to the
Summary of Product of Characteristics Unwillingness to comply with regular assessments of
response and performance of study-related procedures Any condition considered relevant for
proper performance of the study or risk to the patients, at the discretion of the
investigator